Article Figures & Tables
Figures
- Figure 1
Indicator rating criteria matrix.
- Figure 2
Modified Delphi panel process.
Tables
- Table 1: Results as applied in Electronic Medical Record Administrative data Linked Database (EMRALD)
Quality indicator Numerator Denominator Percentage Prevalence, incidence and mortality 1. Patients with stage 3 or greater chronic kidney disease who have it documented in their cumulative patient profile* 1856 6848 27.1 Screening, diagnosis & risk factors 2. Percentage of patients with an initial eGFR < 60 mL/min per 1.73 m2 with an eGFR within 6 months* 4068 8573 47.5 3. Percentage of patients with an initial† eGFR < 60 mL/min per 1.73 m2 with an ACR within 6 months* 1400 8573 16.3 4. Percentage of patients with risk factors for chronic kidney disease (diabetes, hypertension) with an eGFR in the past 18 months 23 998 32 637 73.5 5. Percentage of patients with risk factors for chronic kidney disease (diabetes, hypertension) with an ACR in the past 18 months 9291 32 637 28.5 Management 6. Percentage of patients with chronic kidney disease with an eGFR in the past 18 months 6190 6848 90.4 7. Percentage of patients with chronic kidney disease with an ACR in the past 18 months 2341 6848 34.2 8. Percentage of patients with chronic kidney disease with a BP recorded in the past 9 months 5692 6848 83.1 9. Percentage of patients with diabetes and albuminuria (moderately or severely increased ACR ≥ 3 mg/mmol) with a BP recorded in the past 9 months 5439 6320 86.1 10. Percentage of patients with chronic kidney disease with a most recent BP < 140/90 mm Hg, or with chronic kidney disease and diabetes with a most recent BP < 130/80 mm Hg 4465 6848 65.2 11. Percentage of patients with diabetes and albuminuria (moderately or severely increased ACR ≥ 3 mg/mmol) who were prescribed an ACE inhibitor or ARB unless a contraindication or adverse effects are recorded 3734 4997 74.7 12. Percentage of patients with chronic kidney disease who had a serum potassium test 7-30 days after initial ACE inhibitor-ARB prescription* 2944 4965 59.3 13. Percentage of patients with chronic kidney disease with an ACE inhibitor and an ARB prescription on the same day* 48 6848 0.7 14. Percentage of patients with chronic kidney disease and ≥ 1 prescription for NSAIDs* 99 6848 1.4 15. Percentage of patients ≥ 50 years and ≤ 80 years of age with chronic kidney disease taking a statin unless contraindicated 2236 3701 60.4 16. Percentage of patents with chronic kidney disease who received an influenza vaccine in the past year unless contraindicated 4493 6848 65.6 Referral to a specialist 17. Percentage of patients aged < 80 years with a referral to a nephrologist for eGFR < 30 mL/min per 1.73 m2 339 508 66.7 Note: ACE = angiotensin-converting enzyme, ACR = albumin-creatinine ratio, ARB = angiotensin II receptor blocker, BP = blood pressure, eGFR = estimated glomerular filtration rate, NSAID = nonsteroidal anti-inflammatory drug.
*Modified to be feasible to measure.
†First eGFR < 60 mL/min per 1.73 m2 at least 6 months before the load date of the electronic medical record.
In this issue
Article tools
Respond to this article
Quality indicators for the detection and management of chronic kidney disease in primary care in Canada derived from a modified Delphi panel approach
